Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00389142 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Identifying Genetic Causes of IC/BPS

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study description expanded, about 6 words Site contact updated · Publications: details revised at 1 of 2 entriesv12 Show all 3 changesShow less
    • Site contact updated
    • Publications: details revised at 1 of 2 entries

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Dec 31, 2025 to Dec 31, 2030 Enrollment target: 750 to 1000 · Completion date: Dec 31, 2026 to Dec 31, 2030 · Eligibility criteria revised · 2 morev11 Show all 6 changesShow less
    • Enrollment target: 750 to 1000
    • Completion date: Dec 31, 2026 to Dec 31, 2030
    • Eligibility criteria revised
    • Publications: 1 to 2
    • Study description shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv10
  4. Enrollment target: 500 to 750 Site contact updated · Study description expanded, about 5 words · Study title shortened, about 1 wordv9 Show all 4 changesShow less
    • Site contact updated
    • Study description expanded, about 5 words
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Eligibility criteria revised Study description expanded, about 12 wordsv8 Show all 2 changesShow less
    • Study description expanded, about 12 words

    See this version in full on ClinicalTrials.gov ↗

Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: Dec 31, 2020 to Dec 31, 2025 Completion date: Dec 31, 2021 to Dec 31, 2026 · Study site revisedv7 Show all 3 changesShow less
    • Completion date: Dec 31, 2021 to Dec 31, 2026
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study description expanded, about 49 words Eligibility criteria expanded, about 3 wordsv6 Show all 2 changesShow less
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Dec 31, 2020 Completion date: Jun 2012 to Dec 31, 2021 · Start date: Jan 2006 to Jan 15, 2006 · Eligibility criteria shortened, about 7 words · 5 morev5 Show all 9 changesShow less
    • Completion date: Jun 2012 to Dec 31, 2021
    • Start date: Jan 2006 to Jan 15, 2006
    • Eligibility criteria shortened, about 7 words
    • Site contact updated
    • Publications: 2 to 1
    • Study description expanded, about 1 word
    • Collaborators shortened, about 5 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Completion date: Jan 2011 to Jun 2012 Eligibility criteria expanded, about 2 words · Study description expanded, about 3 words · Collaborators expanded, about 5 wordsv4 Show all 4 changesShow less
    • Eligibility criteria expanded, about 2 words
    • Study description expanded, about 3 words
    • Collaborators expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  5. Enrollment target: 100 to 500 Completion date: Jan 2009 to Jan 2011 · Eligibility criteria expanded, about 10 words · Study description expanded, about 25 wordsv3 Show all 4 changesShow less
    • Completion date: Jan 2009 to Jan 2011
    • Eligibility criteria expanded, about 10 words
    • Study description expanded, about 25 words

    See this version in full on ClinicalTrials.gov ↗

  6. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Interstitial cystitis (IC), also called Bladder Pain syndrome (BPS) is a common condition with no known cause or cure. Twin studies and family accounts have suggested that the condition may be genetic or passed down (inherited) from one generation to another. In this study, the investigators are collecting genetic material via blood or saliva and medical information from families in North America in an attempt to identify genetic factors that may cause IC/BPS. The investigators are enrolling inviduals with IC/BPS and their family members (family members with and without IC like symptoms). Travel to Boston not required.
Trial Details
NCT Number NCT00389142
Lead Sponsor Boston Children's Hospital
Conditions Interstitial Cystitis, Bladder Pain Syndrome
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov